In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

integrated approach to the prevention of cardiovascular diseases

Session Poster Session III - Friday 08:30 - 12:30

Speaker

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2015

  • Topic : preventive cardiology
  • Sub-topic : Diabetes and the Heart
  • Session type : Poster Session

Authors : Y Tarlovskaya (Kirov,RU), Y Balandina (Kirov,RU), N Maksimchuk-Kolobova (Kirov,RU)

Authors:
Y Tarlovskaya1 , Y Balandina1 , N Maksimchuk-Kolobova1 , 1Kirov State Medical Academy - Kirov - Russian Federation ,

Citation:

Purpose. To compare efficacy of the combinations: to achieve the target level of LDL, BP, HbAc%. Methods. 78 patients with moderate arterial hypertension, type 2 diabetes, dyslipidemia were studied. Patients of group A (25) received perindopril/indapamide/simvastatin, of group B (30) - enalapril/indapamide/simvastatin, of group C (23) - enalapril/hydrochlorothiazide/simvastatin.The target levels: BP<130/80 mmperHg, LDL<2 mmol/L. Hypoglycaemic therapy was focused on the achievement of HbAc%.Results. By the 12th week in group A 60% patients achieved the target level of LDL with the dose of 20 mg, 36% - 40 mg, 4% required "atorvastatin" prescription. In group B 23% patients achieved the target level with the dose of 20 mg, 60% - 40 mg, 3% with "atorvastatin" prescription (?<0.05), 14% failed to reach. In group C 57% patients achieved the target level with the dose of 20 mg, 43% -40 mg.By the 12th week all the patients achieved the target level of BP. The minimal antihypertensive effect was reached in group B (?<0.05). Patients with inefficient doubled dose treatment required amlodipine in the dose of 5 mg (2 patients of group B and 1 patient of group A). By the 12th week the level of HbAc% reduced from 8,21±0,38 to 6,94±0,23% in group A, from 8,58±0,38 to 7,19±0,18% in group B, from 8,61±0,31 to 7,24±0,27% in group C (?<0.05). The individual target level of HbAc% was achieved in 72, 53,3 and 69,5% accordingly (p>0.05). Conclusions. Complex influence on CVD risk factors can guarantee more significant result of the individual parameters and more favorable prognosis for the patient.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are